[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-450233-105":59,"doc-detail-450233-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-implications-of-cd15-antigen-expression-in-patients-with-acute-myeloid-leukemia","Prognostic implications of CD15 antigen expression in patients with acute myeloid leukemia","","The prognostic significance of CD15 antigen in acute myeloid leukemia remains inconsistent across studies, and existing evidence is limited. This research evaluates survival impact of CD15 in de novo AML by analyzing CD15 expression in diagnostic flow-cytometry samples from 676 patients. Using a 20% positivity threshold, the cohort is stratified into CD15-positive and CD15-negative groups, with the latter showing worse remission, higher relapse, and increased mortality. Multivariate analysis identifies CD15 positivity alongside TP53 mutation, ELN risk, transplant status, and laboratory measures as independent OS factors. A nomogram predicts OS with C-index 0.778 and shows improved calibration and net benefit versus ELN, supported by time-dependent ROC performance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-implications-of-cd15-antigen-expression-in-patients-with-acute-myeloid-leukemia/450233/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-implications-of-cd15-antigen-expression-in-patients-with-acute-myeloid-leukemia/450233.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-08","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was CD15 expression measured and how were patients grouped?","Question",{"text":112,"@type":113},"CD15 expression was assessed on diagnostic samples using flow cytometry, and patients were stratified with a 20% positivity threshold into CD15-positive and CD15-negative groups.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What clinical outcomes differed between CD15-positive and CD15-negative patients?",{"text":117,"@type":113},"Compared with CD15-positive patients, the CD15-negative group had a lower complete remission rate, higher relapse rate, and increased mortality, with significantly shorter overall survival and disease-free survival.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were identified as independent prognostic variables for overall survival?",{"text":121,"@type":113},"Multivariate analysis found independent prognostic associations with OS for CD15 positivity, TP53 mutation, ELN risk category, bone marrow transplant status, white blood cell counts, and hemoglobin levels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},450233,1791240419,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Clinical and Experimental Medicine (2026) 26:84  \n[https://doi.org/10.1007/s10238-025-01970-y](https://doi.org/10.1007/s10238-025-01970-y)  \nRESEARCH  \nPrognostic implications of CD15 antigen expression in patients with acute myeloid leukemia  \nZhen Li1 · Jiegang Xu1 · Shixue Liu3 · Ya Tan1 · Ping Wang1 · Li Wang2 · Shuangnian Xu1  \nReceived: 26 January 2025 / Accepted: 4 November 2025 © The Author(s) 2025  \nAbstract  \nThe prognostic significance of CD15 antigen in acute myeloid leukemia has been evaluated with conflicting results in various studies. However, existing results are limited and further investigation into additional prognostic parameters is necessary. This study aimed to evaluate the impact of CD15 antigen on survival prognosis in patients with de novo AML (dn-AML) . We analyzed CD15 antigen expression on diagnostic samples from 676 patients with dn-AML by flow cytometry. Utilizing a 20% positivity threshold, the cohort was stratified into CD15 positivity (56.07%) and CD15 negativity (43.93%) groups. The CD15 negativity group demonstrated a lower complete remission rate (P= 0.006), a higher relapse rate (P= 0.002) and increased mortality (P\u003C0.001) compared to the CD15 positivity group. According to the log-rank test, the CD15 negativity group exhibited significantly shorter overall survival (OS) (P\u003C0.001) and disease-free survival (DFS) (P\u003C0.001) . Multivariate analysis identified CD15-positivity, TP53 mutation, European Leukemia Net (ELN) risk category, bone marrow transplant status, white blood cell counts and hemoglobin levels as independent prognostic factors associated with OS. A visualized nomogram was developed to predict OS and demonstrating notable performance with a C-index of 0.778. Compared to the ELN risk model, calibration plots and decision curve analyses indicated superior discrimination, calibration and net benefits. The time-dependent receiver operating characteristic (ROC) curves for 1-, 2-, and 3-year survival also performed robustly (AUC = 0.256, 0.154, and 0.126 respectively) . Our study provides a comprehensive perspective on the role ofCD15 antigen as an independent prognostic marker in dn-AML patients. To some extent, this prognostic model leverages readily available clinical data to enhance predictive accuracy, identify potential risks and support AML therapeutic decision-making.  \nKeywords CD15 surface antigen · De novo acute myeloid leukemia · Survival · Prognosis  \nIntroduction  \nAcute myeloid leukemia (AML) is a hematological malignancy characterized by the clonal proliferation of immature blood cells, resulting in impaired hematopoiesis and  \n􀀍 Ping Wang [79157171@qq.com](79157171@qq.com)  \n􀀍 Shuangnian Xu [xushuangnian@tmmu.edu.cn](xushuangnian@tmmu.edu.cn)  \n1 Center for Hematology, Southwest Hospital, Army Medical University, Chongqing, China  \n2 Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China  \n3 Department of Urology, Shapingba Hospital affiliated to Chongqing University, Chongqing, China  \nsubsequent myeloblasts.  \nfailure that presents a spectrum of clinical syndromes, including anemia, bleeding and infection [1] . Currently, the treatment of AML remains a significant challenge because of its heterogeneity and high recurrence and mortality rates worldwide [2] . Standard treatment protocols involve a combination of induction chemotherapy based on anthracyclinesand cytarabine, followed by cytarabine-based chemotherapy or stem cell transplantation for postremission consolidation [3] . Contemporary therapeutic strategies utilize risk stratification and rely on prognostic factors such as patient age, white blood cell count, cytogenetic or molecular genetic abnormalities, central nervous system or extramedullary involvement, and minimal residual disease (MRD) status [4] . Despite the use of these established protocols, treatment responses can vary significantly even among patients categorized within the same risk group [5] . ","cbCaivF8He4RpXdn","https://ap.wps.com/l/cbCaivF8He4RpXdn","pdf",2403495,12,"English","# Abstract\n# Introduction","[{\"question\":\"How was CD15 expression measured and how were patients grouped?\",\"answer\":\"CD15 expression was assessed on diagnostic samples using flow cytometry, and patients were stratified with a 20% positivity threshold into CD15-positive and CD15-negative groups.\"},{\"question\":\"What clinical outcomes differed between CD15-positive and CD15-negative patients?\",\"answer\":\"Compared with CD15-positive patients, the CD15-negative group had a lower complete remission rate, higher relapse rate, and increased mortality, with significantly shorter overall survival and disease-free survival.\"},{\"question\":\"Which factors were identified as independent prognostic variables for overall survival?\",\"answer\":\"Multivariate analysis found independent prognostic associations with OS for CD15 positivity, TP53 mutation, ELN risk category, bone marrow transplant status, white blood cell counts, and hemoglobin levels.\"}]","Prognostic implications of CD15 antigen expression in patients with acute myeloid leukemia | PDF",1790732589]